EUCTR2009-009656-20-DE进行中（未招募）1 期
Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease - SUN-AK
Charite Universitaetsmedizin Berlin0 个研究点目标入组 50 人开始时间: 2009年3月13日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Early stage of AD (Diagnosis DSM-IV and NINCDS/ADRDA, Dubois-criteria 2007)
- •Age 60-100
- •MMSE 18-26
- •Patient lives at home with at least one relative who perform external ratings/assessment
- •co-medication with Donepezil (Aricept®, Pfizer Pharma GmbH) or Rivastigmin (Exelon®,
- •Novartis Pharma) or Galantamin
- •(Reminyl®, Janssen-Cilag) with at least 3 months of existing stable medication
- •maximum of 2 cups of black tea/die, no green tea, not more than > 500 ml/die of grapefruit juice
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •co-medication with NSAIDs (longterm medication) (ASS is not an exclusion criteria), Gingko- or other natural extracts, other anti-dementiva except of Donepezil, Rivastigmin, Galantamin and Amantadin-Derivaten, wie Memantine (Axura®, Ebixa®)
- •familial autosomal-dominant inherited AD
- •instable medical condition
- •other primary psychiatric/neurologic disorders (psychiatric/neurologic changes in the context of the AD are no exclusion criteria)
- •missing informed consent
- •no readiness to save and refer pseudonym personal data
- •hospitalisation due to juridical or legal regulation
- •any condition disturbing or making MRI and other measures inpossible
- •clinically relevant GI-disorders at screening and 1 year before
- •clinically relevant lung, infectious, heart or other CNS disorders, clinical or paraclinical suspicion of TBC, history of vascular CNS-disorders at screening and 1 year before
- •clinically relevant liver disorders at screening and 1 year before
- •clinically relevant functional disorders of liver, kidney or bone marrow (for definion see protocol)
- •known allergy of Gd-DTPA
- •known allergy of elements of Sunphenon EGCg or additives of Sunphenon EGCg resp. placebo
- •longterm livertoxic medication
- •Cuurent intake of cytochrom P450 3A4-inhibitors or -inductors, such as antimycotics of the azol-type or macrolid-antibiotics
- •Clinical-anamnestic or paraclinical manifestations suggesting an alcohol or drug abuse
- •Participation in any clinical trial < 3 months prior to screening or ongoing
- •Any medical, psychiatric or other condition which might constrain the ability of the patient to understand the informed consent, to give consent, to adhere to the protocl or to accomplish the study
- •massive and extended sun exposure
研究者
相似试验
进行中（未招募）
1 期
SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular DystrophyDuchenne Muscular DystrophyEUCTR2009-016482-28-DECharite Universitätsmedizin Berlin40
进行中（未招募）
不适用
Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis - Sunphenon in RR-MSrelapsing-remitting multiple sclerosisICD classification: G35.1EUCTR2006-006323-39-DECharité-Universitätsmedizin Berlin100
已完成
1 期
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)Relapsing-remitting Multiple SclerosisNCT00525668Charite University, Berlin, Germany120
已完成
2 期
Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s DiseaseAlzheimer's DiseaseNCT00951834Charite University, Berlin, Germany21
已完成
2 期
Sunphenon in Progressive Forms of Multiple SclerosisMultiple SclerosisNCT00799890Friedemann Paul61